Although IFN-I has been clinically prescribed for preventing RRMS relapses, prolonged neuroinflammatory features of IFN-I are observed in Aicardi–Goutières syndrome (AGS) [27], a rare hereditary disease with a constitutive overexpression of IFN-I due to a monogenic mutation in IFN signal-related genes. The gene discussed is IFNA1; the disease is Aicardi-Goutieres syndrome.